FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147222542> ?p ?o ?g. }

• W2147222542 endingPage "843" @default.
• W2147222542 startingPage "838" @default.
• W2147222542 abstract "BACKGROUND: Raltegravir and maraviroc represent new, important resources for HIV-infected patients with intolerance or resistance to other antiretroviral agents. The safety and efficacy of both drugs have been investigated, but there is no information on possible pharmacokinetic interactions between these 2 drugs in clinical practice. OBJECTIVE: To evaluate raltegravir plasma concentrations in heavily treatment-experienced patients receiving salvage regimens and explore, in a preliminary assessment, the potential influence of maraviroc coadministration and other cofactors on raltegravir trough concentrations (C trough ). METHODS: Fifty-four HIV-infected patients with triple class (nucleoside reverse transcriptase inhibitor, nonnucleoside reverse transcriptase inhibitor, protease inhibitor) treatment experience starting raltegravir 400 mg twice daily, with (n = 11) or without (n = 43) concomitant maraviroc 300 mg twice daily, were evaluated. All regimens included at least 3 drugs of at least 2 different classes. Raltegravir plasma C trough , after at least 1 month of treatment, were analyzed to compare groups of patients taking raltegravir only and raltegravir plus maraviroc. Immunovirological (CD4, HIV-RNA) and clinical data after 6 months of treatment were also collected and described. RESULTS: Raltegravir plasma C trough showed a large variability (range <0.020-2.47 μg/mL). Median levels were similar in the 2 groups (raltegravir + maraviroc 0.104 μg/mL, range 0.025−0.826; raltegravir 0.090 μg/mL, range <0.020-2.47, p = 0.400). Detectable (>0.02 μg/mL) raltegravir concentrations were observed in all patients receiving raltegravir + maraviroc and in 74% of patients receiving raltegravir alone (p = 0.060). After 6 months of treatment, the 2 groups had similar clinical, virologic, and immunologic conditions. CONCLUSIONS: Coadministration of maraviroc does not seem to have any relevant effects on raltegravir plasma C trough in heavily treatment-experienced patients receiving salvage regimens. Further studies should evaluate the potential additional benefits of maraviroc coadministration in terms of virologic and immunologic response." @default.
• W2147222542 created "2016-06-24" @default.
• W2147222542 creator A5013319218 @default.
• W2147222542 creator A5017481279 @default.
• W2147222542 creator A5028118033 @default.
• W2147222542 creator A5028537284 @default.
• W2147222542 creator A5044885843 @default.
• W2147222542 creator A5046931461 @default.
• W2147222542 creator A5052591896 @default.
• W2147222542 creator A5059262615 @default.
• W2147222542 creator A5063748250 @default.
• W2147222542 creator A5074037938 @default.
• W2147222542 creator A5075572192 @default.
• W2147222542 creator A5075956703 @default.
• W2147222542 creator A5091226902 @default.
• W2147222542 date "2010-05-01" @default.
• W2147222542 modified "2023-09-27" @default.
• W2147222542 title "Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir with and without Maraviroc Coadministration" @default.
• W2147222542 cites W1965354305 @default.
• W2147222542 cites W1983837630 @default.
• W2147222542 cites W1988264086 @default.
• W2147222542 cites W1990380448 @default.
• W2147222542 cites W2015171620 @default.
• W2147222542 cites W2045730529 @default.
• W2147222542 cites W2046594098 @default.
• W2147222542 cites W2049894560 @default.
• W2147222542 cites W2053125329 @default.
• W2147222542 cites W2075870842 @default.
• W2147222542 cites W2087525467 @default.
• W2147222542 cites W2150504993 @default.
• W2147222542 cites W2153000646 @default.
• W2147222542 cites W2153650518 @default.
• W2147222542 cites W2163866093 @default.
• W2147222542 cites W2165447838 @default.
• W2147222542 cites W2169218167 @default.
• W2147222542 doi "https://doi.org/10.1345/aph.1m688" @default.
• W2147222542 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20371753" @default.
• W2147222542 hasPublicationYear "2010" @default.
• W2147222542 type Work @default.
• W2147222542 sameAs 2147222542 @default.
• W2147222542 citedByCount "17" @default.
• W2147222542 countsByYear W21472225422012 @default.
• W2147222542 countsByYear W21472225422013 @default.
• W2147222542 countsByYear W21472225422015 @default.
• W2147222542 countsByYear W21472225422016 @default.
• W2147222542 countsByYear W21472225422021 @default.
• W2147222542 countsByYear W21472225422022 @default.
• W2147222542 crossrefType "journal-article" @default.
• W2147222542 hasAuthorship W2147222542A5013319218 @default.
• W2147222542 hasAuthorship W2147222542A5017481279 @default.
• W2147222542 hasAuthorship W2147222542A5028118033 @default.
• W2147222542 hasAuthorship W2147222542A5028537284 @default.
• W2147222542 hasAuthorship W2147222542A5044885843 @default.
• W2147222542 hasAuthorship W2147222542A5046931461 @default.
• W2147222542 hasAuthorship W2147222542A5052591896 @default.
• W2147222542 hasAuthorship W2147222542A5059262615 @default.
• W2147222542 hasAuthorship W2147222542A5063748250 @default.
• W2147222542 hasAuthorship W2147222542A5074037938 @default.
• W2147222542 hasAuthorship W2147222542A5075572192 @default.
• W2147222542 hasAuthorship W2147222542A5075956703 @default.
• W2147222542 hasAuthorship W2147222542A5091226902 @default.
• W2147222542 hasConcept C112705442 @default.
• W2147222542 hasConcept C126322002 @default.
• W2147222542 hasConcept C142462285 @default.
• W2147222542 hasConcept C159047783 @default.
• W2147222542 hasConcept C2777302000 @default.
• W2147222542 hasConcept C2778899366 @default.
• W2147222542 hasConcept C2779182219 @default.
• W2147222542 hasConcept C2780404665 @default.
• W2147222542 hasConcept C2909675724 @default.
• W2147222542 hasConcept C2911091166 @default.
• W2147222542 hasConcept C2993143319 @default.
• W2147222542 hasConcept C3013748606 @default.
• W2147222542 hasConcept C31785415 @default.
• W2147222542 hasConcept C71924100 @default.
• W2147222542 hasConcept C98274493 @default.
• W2147222542 hasConceptScore W2147222542C112705442 @default.
• W2147222542 hasConceptScore W2147222542C126322002 @default.
• W2147222542 hasConceptScore W2147222542C142462285 @default.
• W2147222542 hasConceptScore W2147222542C159047783 @default.
• W2147222542 hasConceptScore W2147222542C2777302000 @default.
• W2147222542 hasConceptScore W2147222542C2778899366 @default.
• W2147222542 hasConceptScore W2147222542C2779182219 @default.
• W2147222542 hasConceptScore W2147222542C2780404665 @default.
• W2147222542 hasConceptScore W2147222542C2909675724 @default.
• W2147222542 hasConceptScore W2147222542C2911091166 @default.
• W2147222542 hasConceptScore W2147222542C2993143319 @default.
• W2147222542 hasConceptScore W2147222542C3013748606 @default.
• W2147222542 hasConceptScore W2147222542C31785415 @default.
• W2147222542 hasConceptScore W2147222542C71924100 @default.
• W2147222542 hasConceptScore W2147222542C98274493 @default.
• W2147222542 hasIssue "5" @default.
• W2147222542 hasLocation W21472225421 @default.
• W2147222542 hasLocation W21472225422 @default.
• W2147222542 hasOpenAccess W2147222542 @default.
• W2147222542 hasPrimaryLocation W21472225421 @default.
• W2147222542 hasRelatedWork W1983697728 @default.
• W2147222542 hasRelatedWork W2004424444 @default.

• next